AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19481279 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (moderate dose: 10 mg)
Number of subjects: 28
Study 19481279 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 28
Study 18657653 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic spontaneous reperfusion (ECG SR)
Number of subjects: 585
Study 18657653 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic spontaneous reperfusion (Angiographic SR)
Number of subjects: 585
Study 16177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (Amiodarone)
Number of subjects: 0
Study 16177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control (Digoxin and beta-blocker)
Number of subjects: 0
Study 16177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacologic approaches (catheter-based techniques)
Number of subjects: 0
Study 16177674 — intervention group
Group type: EXPERIMENTAL
Intervention: AV node ablation and pacemaker implantation
Number of subjects: 0
Study 16177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulation
Number of subjects: 0
Study 16177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of a defibrillator
Number of subjects: 0
Study 16388222 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic with dexamethasone
Number of subjects: 40
Study 16388222 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic without dexamethasone
Number of subjects: 40
Study 10885210 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8843283 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline formulation of erythromycin ethylsuccinate (CEE) at 1,000 mg every 12 h
Number of subjects: 10
Study 8843283 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous formulation of erythromycin ethylsuccinate (AEE) at 500 mg every 12 h
Number of subjects: 10
Study 8843283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1503486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpiramide + amikacin (CPM + AMK)
Number of subjects: 141
Study 1503486 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin + amikacin (PIPC + AMK)
Number of subjects: 141
Study 6233398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg intramuscular (IM) MPA (high dose) daily for four weeks
Number of subjects: 210
Study 6233398 — intervention group
Group type: COMPARATOR
Intervention: 500 mg IM MPA (low dose) twice weekly for four weeks
Number of subjects: 210
Study 31176466 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test adapted to children
Number of subjects: 81
Study 31176466 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study 30202836 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark
Number of subjects: 58
Study 30202836 — intervention group
Group type: EXPERIMENTAL
Intervention: Swede-Vent
Number of subjects: 58
Study 30202836 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-Vent
Number of subjects: 58
Study 27640987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 2299
Study 27640987 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BP (systolic BP<120 mmHg, diastolic BP <70 mmHg)
Number of subjects: 2299
Study 27640987 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics
Number of subjects: 2299
Study 24272917 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 1 mg/kg Q2W
Number of subjects: 48
Study 24272917 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 2 mg/kg Q2W
Number of subjects: 48
Study 24272917 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 2 mg/kg Q4W
Number of subjects: 48
Study 24272917 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 3 mg/kg Q4W
Number of subjects: 48
Study 24272917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22342408 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) cystoscopy associated with bipolar plasma vaporization (BPV)
Number of subjects: 220
Study 22342408 — intervention group
Group type: COMPARATOR
Intervention: White light cystoscopy (WLC) and monopolar transurethral resection of bladder tumors (TURBT)
Number of subjects: 220
Study 20039450 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position (Group A)
Number of subjects: 90
Study 20039450 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Group B)
Number of subjects: 90
Study 20039450 — intervention group
Group type: EXPERIMENTAL
Intervention: Right supine position (Group C)
Number of subjects: 90
Study 18574390 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid for 3 months (n = 19)
Number of subjects: 34
Study 18574390 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months (n = 15)
Number of subjects: 34
Study 18574390 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 34
Study 18574390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15757595 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent
Number of subjects: 1307
Study 15757595 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1307
Study 12472925 — intervention group
Group type: COMPARATOR
Intervention: Patient with coronary artery disease (CAD)
Number of subjects: 1640
Study 12472925 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with PAD
Number of subjects: 1640
Study 12472925 — intervention group
Group type: COMPARATOR
Intervention: Patient with no clinically evident atherosclerosis (no disease)
Number of subjects: 1640
Study 12472925 — intervention group
Group type: COMPARATOR
Intervention: Patient with CAD
Number of subjects: 1640
Study 12472925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologists
Number of subjects: 1640
Study 10084567 — intervention group
Group type: COMPARATOR
Intervention: Continuous placebo
Number of subjects: 17
Study 10084567 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lipids
Number of subjects: 17
Study 7778179 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 28
Study 7778179 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (600 mg/day in 2 doses)
Number of subjects: 28
Study 7778179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 2190460 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate, 20 mg 3 times daily
Number of subjects: 28
Study 358755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 200 mg
Number of subjects: 44
Study 358755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 400 mg
Number of subjects: 44
Study 358755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 600 mg
Number of subjects: 44
Study 358755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 44
Study 31491792 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing the Standard (ATS) mechanical valve
Number of subjects: 90
Study 31491792 — intervention group
Group type: COMPARATOR
Intervention: St. Jude Medical (SJM) mechanical valve
Number of subjects: 90
Study 31491792 — intervention group
Group type: COMPARATOR
Intervention: Carbomedics (CM) mechanical valve
Number of subjects: 90
Study 31881823 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 264
Study 31881823 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 264
Study 28072709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - bolus dose of 30 mg/kg i.v, maintenance dosage of 2 mg/kg/h
Number of subjects: 100
Study 28072709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 28072709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 100
Study 26429075 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program intervention
Number of subjects: 2062
Study 26429075 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program intervention for 2 years
Number of subjects: 2062
Study 26429075 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program intervention for 1 year
Number of subjects: 2062
Study 26429075 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 2062
Study 24220342 — intervention group
Group type: EXPERIMENTAL
Intervention: Community practice site (intervention)
Number of subjects: 0
Study 24220342 — intervention group
Group type: COMPARATOR
Intervention: Hospital site (usual care)
Number of subjects: 0
Study 21142377 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger prevention focus (measured as a chronic disposition)
Number of subjects: 0
Study 21142377 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger prevention focus (experimentally induced as a temporary state)
Number of subjects: 0
Study 21142377 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about normativeness of managing behavior
Number of subjects: 0
Study 21142377 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about effectiveness of managing behavior
Number of subjects: 0
Study 21142377 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of superior-subordinate dyads
Number of subjects: 0
Study 18086165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, or 100 mg)
Number of subjects: 307
Study 18086165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 17063108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam
Number of subjects: 252
Study 17063108 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with lidocaine throat spray
Number of subjects: 252
Study 17063108 — intervention group
Group type: COMPARATOR
Intervention: Placebo sedation and placebo throat spray
Number of subjects: 252
Study 17063108 — intervention group
Group type: COMPARATOR
Intervention: No intravenous cannula nor throat spray (control group)
Number of subjects: 252
Study 12952691 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits via analogue video-phones, 2 visits per week
Number of subjects: 10
Study 12952691 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits via analogue video-phones
Number of subjects: 10
Study 11200803 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients (parents and children)
Number of subjects: 40
Study 11200803 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial influences
Number of subjects: 40
Study 9385861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry meals (normal diet but no water from 1 hour before meals to 1 hour after meals) for one year
Number of subjects: 220
Study 9385861 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg bd for 3 months
Number of subjects: 220
Study 9385861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry meals
Number of subjects: 220
Study 7974316 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support (IPS) with mean airway pressure 12-15 cm H2O
Number of subjects: 8
Study 7974316 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) 6 cm H2O
Number of subjects: 8
Study 7974316 — intervention group
Group type: COMPARATOR
Intervention: Oxygen at 2 l/min via a mask
Number of subjects: 8
Study 7974316 — intervention group
Group type: COMPARATOR
Intervention: Control walk using a sham circuit (breathing air via an oxygen mask at 2 l/min from an unlabelled cylinder)
Number of subjects: 8
Study 7974316 — intervention group
Group type: COMPARATOR
Intervention: Baseline walk (walking freely on the treadmill)
Number of subjects: 8
Study 2645086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active involvement of staff only
Number of subjects: 201
Study 2645086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active involvement of residents only
Number of subjects: 201
Study 2645086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active involvement of both residents and staff
Number of subjects: 201
Study 2645086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 201
Study 1162529 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of fenoterol
Number of subjects: 30
Study 1162529 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of fenoterol
Number of subjects: 30
Study 31931025 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric scaler (Tigon+®) with warmed water irrigation (approx 36 °C)
Number of subjects: 140
Study 31931025 — intervention group
Group type: COMPARATOR
Intervention: Piezoelectric scaler (Tigon+®) with room temperature irrigation (approx 20 °C)
Number of subjects: 140
Study 31931025 — intervention group
Group type: COMPARATOR
Intervention: Magnetostrictive scaler (Cavitron Select SPS 30K®) with room temperature irrigation (approx 20 °C)
Number of subjects: 140
Study 30741567 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 20-30 mg/d (20 mg/d for <30 kg and 30 mg/d for >30 kg)
Number of subjects: 54
Study 30741567 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) 20-30 mg/d (20 mg/d for <30 kg and 30 mg/d for >30 kg)
Number of subjects: 54
Study 30741567 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron)
Number of subjects: 54
Study 30741567 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 54
Study 30741567 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) and Methylphenidate (MPH)
Number of subjects: 54
Study 28727160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate and chlorhexidine diacetate mouth rinse (Zn/CHX)
Number of subjects: 46
Study 28727160 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 46
Study 24754798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%) infiltration into the surgical wound (Group LA)
Number of subjects: 90
Study 24754798 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (Group No LA)
Number of subjects: 90
Study 23630039 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (80 mg·kg‐1BM·day‐1)
Number of subjects: 18
Study 23630039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21212771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (6 face-to-face sessions, TV locking device, home-based activities)
Number of subjects: 90
Study 21212771 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 19743907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pentosan polysulfate sodium
Number of subjects: 41
Study 19743907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and nocturia
Number of subjects: 41
Study 19743907 — intervention group
Group type: EXPERIMENTAL
Intervention: Being currently unmarried
Number of subjects: 41
Study 19743907 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed, currently unmarried, obese, never pregnant, and ever use of oral contraceptive
Number of subjects: 41
Study 19743907 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 41
Study 17173716 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational tobacco intervention (MTI)
Number of subjects: 75
Study 17173716 — intervention group
Group type: COMPARATOR
Intervention: Brief advice or care as usual
Number of subjects: 75
Study 15812967 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH funded trials (n = 52)
Number of subjects: 280
Study 15812967 — intervention group
Group type: COMPARATOR
Intervention: Other trials (not NIH funded)
Number of subjects: 280
Study 11174337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (0.625 mg)
Number of subjects: 64
Study 11174337 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose ramipril (10 mg)
Number of subjects: 64
Study 11174337 — intervention group
Group type: COMPARATOR
Intervention: All patients
Number of subjects: 64
Study 8883014 — intervention group
Group type: EXPERIMENTAL
Intervention: CUP haemodialysis
Number of subjects: 10
Study 8883014 — intervention group
Group type: COMPARATOR
Intervention: PAN haemodialysis
Number of subjects: 10
Study 1424428 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 15
Study 1424428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3890604 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60
Study 3890604 — intervention group
Group type: COMPARATOR
Intervention: Morphine (standard analgesic)
Number of subjects: 60
Study 30170533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pills
Number of subjects: 271
Study 30170533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal gels
Number of subjects: 271
Study 30170533 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly product use
Number of subjects: 271
Study 29504386 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 32
Study 29504386 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 26872219 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment by midwives
Number of subjects: 1010
Study 26872219 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol treatment by physicians
Number of subjects: 1010
Study 25060825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-term radiotherapy (PRT) + Total mesorectal excision (TME)
Number of subjects: 606
Study 25060825 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 606
Study 23225854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of borneol (30.0 mg/kg)
Number of subjects: 0
Study 23225854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of borneol (30.0 mg/kg)
Number of subjects: 0
Study 23225854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of borneol (30.0 mg/kg)
Number of subjects: 0
Study 18801829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (24 UI)
Number of subjects: 29
Study 18801829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17603306 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0
Study 16035378 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg tablets (test formulation)
Number of subjects: 26
Study 16035378 — intervention group
Group type: COMPARATOR
Intervention: Amoxil BD 875 mg tablets (reference formulation)
Number of subjects: 26
Study 11753007 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous parecoxib
Number of subjects: 12
Study 11753007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9696517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg/day
Number of subjects: 319
Study 9696517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg/day
Number of subjects: 319
Study 9696517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 1200 mg/day
Number of subjects: 319
Study 9696517 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride 100 mg/day
Number of subjects: 319
Study 9696517 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 16 mg/day
Number of subjects: 319
Study 7654731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (10 mg/day)
Number of subjects: 18
Study 7654731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 18
Study 7654731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 18
Study 2127139 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-rich fish oil diet (2 g/day)
Number of subjects: 125
Study 2127139 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-rich fish oil diet (6 g/day)
Number of subjects: 125
Study 2127139 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction diet (combined with fish oil)
Number of subjects: 125
Study 2127139 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFA
Number of subjects: 125
Study 371629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3904 mg daily for 1 week)
Number of subjects: 16
Study 371629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen (2400 mg daily for 1 week)
Number of subjects: 16
Study 371629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30286628 — intervention group
Group type: EXPERIMENTAL
Intervention: Invagination of the hernial sac (Group A)
Number of subjects: 70
Study 30286628 — intervention group
Group type: COMPARATOR
Intervention: Excision of the hernial sac (Group B)
Number of subjects: 70
Study 30286628 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study 27780336 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (n = 146)
Number of subjects: 293
Study 27780336 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (n = 147)
Number of subjects: 293
Study 26032729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored delirium prevention protocol applied daily for the first 7 days of ICU hospitalization
Number of subjects: 123
Study 26032729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored delirium prevention protocol
Number of subjects: 123
Study 26032729 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 23179146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 423
Study 23179146 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no intervention
Number of subjects: 423
Study 22055098 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 206
Study 19691461 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir (ACV)
Number of subjects: 0
Study 19691461 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antiviral agents
Number of subjects: 0